CY1119714T1 - Ενωσεις αναστολεων - Google Patents

Ενωσεις αναστολεων

Info

Publication number
CY1119714T1
CY1119714T1 CY20171101358T CY171101358T CY1119714T1 CY 1119714 T1 CY1119714 T1 CY 1119714T1 CY 20171101358 T CY20171101358 T CY 20171101358T CY 171101358 T CY171101358 T CY 171101358T CY 1119714 T1 CY1119714 T1 CY 1119714T1
Authority
CY
Cyprus
Prior art keywords
compounds
present
relates
unions
suspension
Prior art date
Application number
CY20171101358T
Other languages
English (en)
Inventor
Swen Hoelder
Julian Blagg
Savade SOLANKI
Hannah Woodward
Sebastien Naud
Vassilios Bavetsias
Peter SHELDRAKE
Paolo INNOCENTI
Kwai-Ming J. Cheung
Butrus Atrash
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of CY1119714T1 publication Critical patent/CY1119714T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ενώσεις του τύπου (I), όπου R, R, Ar, W, Χ και Ζ είναι όλα όπως ορίζονται στο παρόν. Οι ενώσεις της παρούσας εφεύρεσης είναι γνωστό ότι αναστέλλουν τη λειτουργία του σημείου ελέγχου ατράκτου των κινασών Monospindle 1 (Mps1 - γνωστές επίσης ως ΤΤΚ) είτε άμεσα είτε έμμεσα μέσω αλληλεπίδρασης με την ίδια την κινάση Mps 1. Συγκεκριμένα, η παρούσα εφεύρεση αφορά τη χρήση αυτών των ενώσεων ως θεραπευτικών παραγόντων για την αντιμετώπιση ή/και την πρόληψη υπερπλαστικών παθήσεων, όπως ο καρκίνος. Η παρούσα εφεύρεση αφορά επίσης διαδικασίες για την παρασκευή αυτών των ενώσεων, καθώς και φαρμακευτικών συνθέσεων που τις εμπεριέχουν.
CY20171101358T 2012-09-07 2017-12-29 Ενωσεις αναστολεων CY1119714T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1216017.2A GB201216017D0 (en) 2012-09-07 2012-09-07 Inhibitor compounds
PCT/GB2013/052360 WO2014037750A1 (en) 2012-09-07 2013-09-09 Inhibitor compounds

Publications (1)

Publication Number Publication Date
CY1119714T1 true CY1119714T1 (el) 2018-06-27

Family

ID=47137117

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101358T CY1119714T1 (el) 2012-09-07 2017-12-29 Ενωσεις αναστολεων

Country Status (22)

Country Link
US (6) US9409907B2 (el)
EP (2) EP2892889B1 (el)
JP (2) JP6216791B2 (el)
CN (1) CN104837829B (el)
AU (2) AU2013311434B2 (el)
BR (1) BR112015004489B1 (el)
CA (1) CA2884006C (el)
CY (1) CY1119714T1 (el)
DK (2) DK3293183T3 (el)
ES (2) ES2742442T3 (el)
GB (1) GB201216017D0 (el)
HK (1) HK1211921A1 (el)
HR (1) HRP20171835T1 (el)
HU (1) HUE036259T2 (el)
LT (1) LT2892889T (el)
NO (1) NO2892889T3 (el)
PL (1) PL2892889T3 (el)
PT (1) PT2892889T (el)
RS (1) RS56750B1 (el)
RU (1) RU2673079C2 (el)
SI (1) SI2892889T1 (el)
WO (1) WO2014037750A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
AU2009225407B2 (en) 2008-03-21 2013-09-05 The General Hospital Corporation Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
PL3035936T3 (pl) 2013-08-23 2019-08-30 Neupharma, Inc. Pewne jednostki chemiczne, kompozycje i sposoby
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
JP6616934B2 (ja) * 2014-05-22 2019-12-04 株式会社 資生堂 レナリドミドの光学分割方法
US10947201B2 (en) 2015-02-17 2021-03-16 Neupharma, Inc. Certain chemical entities, compositions, and methods
CA2981844A1 (en) 2015-04-17 2016-10-20 Netherlands Translational Research Center B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
KR102601320B1 (ko) * 2015-05-29 2023-11-10 데이진 화-마 가부시키가이샤 피리도[3,4-d]피리미딘 유도체 및 그 약학적으로 허용되는 염
KR102591886B1 (ko) * 2015-07-21 2023-10-20 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용
GB201522532D0 (en) * 2015-12-21 2016-02-03 Cancer Rec Tech Ltd Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
US10544106B2 (en) 2016-08-15 2020-01-28 Neupharma, Inc. Certain chemical entities, compositions, and methods
US11261182B2 (en) 2016-11-28 2022-03-01 Teijin Pharma Limited Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof
AU2017364807B2 (en) * 2016-11-28 2021-05-13 Teijin Limited Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
GB201709840D0 (en) * 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
AU2018287988A1 (en) * 2017-06-20 2019-10-10 Breast Cancer Now Methods and medical uses
EP3701304B1 (en) 2017-10-26 2022-05-04 CommScope Connectivity Belgium BVBA Telecommunications system
GB201809460D0 (en) 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
GB201809458D0 (en) 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
EP4328229A2 (en) 2019-10-30 2024-02-28 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
KR102396930B1 (ko) * 2020-01-15 2022-05-12 한국과학기술연구원 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
CN115916747A (zh) * 2020-07-01 2023-04-04 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
US11912668B2 (en) 2020-11-18 2024-02-27 Deciphera Pharmaceuticals, Llc GCN2 and perk kinase inhibitors and methods of use thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2697710A (en) 1953-01-02 1954-12-21 Burroughs Wellcome Co Pyrido (2,3-d) pyrimidines and method of preparing same
US3021332A (en) 1954-01-04 1962-02-13 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
AU711426B2 (en) 1994-11-14 1999-10-14 Warner-Lambert Company 6-aryl pyrido(2,3-d)pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation
AU2542501A (en) 2000-01-25 2001-08-07 Warner-Lambert Company Pyrido(2,3-d)pyrimidine-2,7-diamine kinase inhibitors
US7053070B2 (en) 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
WO2002090360A1 (en) 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030105115A1 (en) 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2002353147A1 (en) 2001-12-13 2003-06-30 Abbott Laboratories 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
AU2003210388B2 (en) 2002-03-07 2007-05-17 F. Hoffmann-La Roche Ag Bicyclic pyridine and pyrimidine P38 Kinase inhibitors
ATE374201T1 (de) * 2002-08-06 2007-10-15 Hoffmann La Roche 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
US20040092521A1 (en) 2002-11-12 2004-05-13 Altenbach Robert J. Bicyclic-substituted amines as histamine-3 receptor ligands
PL376751A1 (pl) 2002-11-12 2006-01-09 Abbott Laboratories Bicykliczne podstawione aminy jako ligandy receptora histaminowego-3
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
DE602006008945D1 (de) 2005-06-28 2009-10-15 Sanofi Aventis Isochinolinderivate als inhibitoren von rho-kinase
AU2006330924B2 (en) * 2005-12-21 2012-03-15 Abbvie Inc. Anti-viral compounds
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
MX2009006627A (es) 2006-12-22 2009-08-12 Novartis Ag Quinazolinas para la inhibicion de pdk1.
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
WO2009032694A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
US20100311965A1 (en) * 2007-12-28 2010-12-09 Carna Biosciences Inc. 2-aminoquinazoline derivative
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
RU2581367C2 (ru) 2010-03-01 2016-04-20 Джи Ти Икс, ИНК. Соединения для лечения рака
GB201011182D0 (en) 2010-07-02 2010-08-18 Wireless Fibre Systems Ltd Riser wireless communications system
WO2012013557A1 (en) * 2010-07-30 2012-02-02 Nerviano Medical Sciences S.R.L. Isoxazolo-quinazolines as modulators of protein kinase activity
ES2377610B1 (es) 2010-09-01 2013-02-05 Institut Químic de Sarriá CETS Fundació Privada Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos.
WO2012052540A1 (en) 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
CA2817460A1 (en) 2010-12-17 2012-06-21 F. Hoffmann-La Roche Ag Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
TWI450891B (zh) 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
BR112013018515B1 (pt) * 2011-01-26 2021-06-29 Nerviano Medical Sciences S.R.I Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US9745191B2 (en) 2011-04-11 2017-08-29 Saudi Arabian Oil Company Auto thermal reforming (ATR) catalytic structures
EP3430907A1 (en) 2011-07-29 2019-01-23 Medivation Prostate Therapeutics LLC Treatment of breast cancer
CA2850394C (en) 2011-10-12 2019-05-21 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
US20160000787A1 (en) 2013-02-26 2016-01-07 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
KR20160085915A (ko) 2013-12-06 2016-07-18 에프. 호프만-라 로슈 아게 국소 진행성 또는 전이성 에스트로겐 수용체 양성 유방암을 치료하기 위한 에스트로겐 수용체 조절자
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
JP2017508469A (ja) 2014-03-11 2017-03-30 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 癌悪性度、予後及び治療に対する反応性の決定
JP2017520603A (ja) 2014-07-14 2017-07-27 シグナル ファーマシューティカルズ，エルエルシー 置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物
WO2016073771A2 (en) 2014-11-06 2016-05-12 Ohio State Innovation Foundation Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
GB201522532D0 (en) 2015-12-21 2016-02-03 Cancer Rec Tech Ltd Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
AU2018287988A1 (en) 2017-06-20 2019-10-10 Breast Cancer Now Methods and medical uses
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Also Published As

Publication number Publication date
CA2884006C (en) 2021-01-19
WO2014037750A1 (en) 2014-03-13
JP6216791B2 (ja) 2017-10-18
US20150239884A1 (en) 2015-08-27
GB201216017D0 (en) 2012-10-24
EP2892889A1 (en) 2015-07-15
US20220402912A1 (en) 2022-12-22
SI2892889T1 (sl) 2017-12-29
US9890157B2 (en) 2018-02-13
AU2013311434B2 (en) 2017-10-19
AU2017268488B2 (en) 2019-06-13
US11897877B2 (en) 2024-02-13
RU2673079C2 (ru) 2018-11-22
US20180141944A1 (en) 2018-05-24
EP2892889B1 (en) 2017-10-18
ES2742442T3 (es) 2020-02-14
PL2892889T3 (pl) 2018-03-30
CN104837829B (zh) 2019-07-05
ES2655194T3 (es) 2018-02-19
BR112015004489A2 (pt) 2017-07-04
US20160220570A1 (en) 2016-08-04
EP3293183A1 (en) 2018-03-14
US9834552B2 (en) 2017-12-05
NO2892889T3 (el) 2018-03-17
DK2892889T3 (en) 2017-12-11
US9409907B2 (en) 2016-08-09
US20200165241A1 (en) 2020-05-28
LT2892889T (lt) 2017-12-11
PT2892889T (pt) 2018-01-09
BR112015004489B1 (pt) 2020-09-29
AU2013311434A1 (en) 2015-04-02
US20160222009A1 (en) 2016-08-04
HRP20171835T1 (hr) 2017-12-29
CA2884006A1 (en) 2014-03-13
JP2015527387A (ja) 2015-09-17
HUE036259T2 (hu) 2018-06-28
US10479788B2 (en) 2019-11-19
DK3293183T3 (da) 2019-08-12
JP6496376B2 (ja) 2019-04-03
JP2018027967A (ja) 2018-02-22
HK1211921A1 (en) 2016-06-03
RS56750B1 (sr) 2018-03-30
CN104837829A (zh) 2015-08-12
RU2015112580A (ru) 2016-10-27
US11046688B2 (en) 2021-06-29
EP3293183B1 (en) 2019-07-24
AU2017268488A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
CY1119714T1 (el) Ενωσεις αναστολεων
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
CY1119901T1 (el) Αναστολεις απομεθυλασων ιστονων
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1119487T1 (el) Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1118061T1 (el) Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση
CY1117352T1 (el) Υποκατεστημενες ιμιδαζοπυριδαζiνες
CY1117200T1 (el) Παραγωγα βενζυλαμινης ως αναστολεις καλλικρεϊνης πλασματος
TR201819138T4 (tr) FGFR Kinaz Modülatörleri Olarak Faydalı Kinoksalin Türevleri
UA111305C2 (uk) Конденсовані лактами арилу та гетероарилу
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
EA201690752A1 (ru) Ингибиторы g12c kras
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου